test Browse by Author Names Browse by Titles of Works Browse by Subjects of Works Browse by Issue Dates of Works

Advanced Search
& Collections
Issue Date   
Sign on to:   
Receive email
My Account
authorized users
Edit Profile   
About T-Space   

T-Space at The University of Toronto Libraries >
University of Toronto at Scarborough >
Bioline International Legacy Collection >
Bioline International Legacy Collection >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1807/8881

Title: Comparative bioavailability study of a new quinine suppository and oral quinine in healthy volunteers
Authors: Babalolaa, C.P.
Adebayo, A.S.
Omotoso, A.
Oyeyinka, A.
Keywords: Quinine, suppository, bioavailability.
Issue Date: 31-Dec-2004
Publisher: Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria
Citation: Tropical Journal of Pharmaceutical Research (ISSN: 1596-5996) Vol 3 Num 1
Abstract: Purpose: There is the need for alternative and more convenient route of quinine (QN) administration in complicated and severe malaria. The purpose of this study is to compare the bioavailability (BA) of a new quinine suppository made from theobroma oil to that of an existing tablet formulation in healthy volunteers. Methods: Six healthy volunteers were administered with 300 mg of QN sulphate as suppository and tablet in a crossover manner. QN concentrations in both plasma and urine at predetermined time points were determined spectrofluorimetrically. Results: Absorption was slower, more variable and lower with the suppository than with the tablet. The time of maximum concentration (Tmax), maximum concentration (Cmax), area under the curve (AUC) and cumulative urinary excretion (Du∞) for the two formulations were also significantly different, with no changes in elimination half-life (t1/2). The respective Cmax and AUC values were 4 to 5 times higher with the tablet (2.32 ± 0.22 μg/ml, 36.31 ± 10.06 μg.h/ml) than with the suppository (0.52 ± 0.37 μg/ml, 7.69 ± 5.79 μg.h/ml). The Du∞ were 9.17 ± 1.11 mg and 2.56 ± 0.55 mg for the tablet and suppository respectively. The relative BA of the suppository was 21.24 ± 16.00 % (95 % C. I., 8.44 -34.04%) from plasma levels and 26.14 ± 7.80 % (95 C.I., 19.90 -32.38 %) from urine excretion. Conclusion: Absorption of this new QN suppository is poor; therefore it may not be therapeutically expedient to substitute it for the tablet form at the same dose. Improving the suppository formulation or increasing the dose in order to increase its BA may be necessary.
URI: http://hdl.handle.net/1807/8881
Other Identifiers: http://www.bioline.org.br/abstract?id=pr04005
Rights: Copyright 2002-2006. TJPR Faculty of Pharmacy, University of Benin, Benin City, Nigeria
Appears in Collections:Bioline International Legacy Collection

Files in This Item:

File Description SizeFormat
pr04005.pdf99.35 kBAdobe PDF

Items in T-Space are protected by copyright, with all rights reserved, unless otherwise indicated.